Concurrent or sequential adjuvant letrozole and radiotherapy after conservative surgery for early-stage breast cancer (CO-HO-RT): a phase 2 randomised trial

The Lancet Oncology

Volumn 11, Issue 3, 2010, Pages 258-265

  Azria, David ^a   Belkacemi, Yazid ^b   Romieu, Gilles ^a   Gourgou, Sophie ^a   Gutowski, Marian ^a   Zaman, Khalil ^c   Moscardo, Carmen Llacer ^a   Lemanski, Claire ^a   Coelho, Michael ^a   Rosenstein, Barry ^d   Fenoglietto, Pascal ^a   Crompton, Nigel EA ^e   Ozsahin, Mahmut ^c  

^a CENTRE VAL D AURELLE   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e VAN ANDEL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; LETROZOLE;

ADJUVANT THERAPY; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER STATISTICS; CARDIOTOXICITY; CLINICAL TRIAL; CONSERVATIVE TREATMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; DRUG SAFETY; EARLY CANCER; FEMALE; FRANCE; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOCYTE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RANDOMIZED CONTROLLED TRIAL; SKIN FIBROSIS; SKIN TOXICITY; SWITZERLAND; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; AROMATASE INHIBITORS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; DERMATITIS; DRUG TOXICITY; FEMALE; HUMANS; MIDDLE AGED; NITRILES; POSTMENOPAUSE; RADIATION-SENSITIZING AGENTS; SURVIVAL ANALYSIS; TRIAZOLES;

EID: 77349127065     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(10)70013-9     Document Type: Article

References (30)

1. Early Breast Cancer Trialists' Collaborative Group. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366 (2005) 2087-2106
2. Thurlimann B., Keshaviah A., Coates A.S., et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353 (2005) 2747-2757
3. Coates A.S., Keshaviah A., Thurlimann B., et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 25 (2007) 486-492
4. Azria D., Larbouret C., Cunat S., et al. Letrozole sensitizes breast cancer cells to ionizing radiation. Breast Cancer Res 7 (2005) 156-163
5. Miller W.R., Hawkins R.A., and Forrest A.P. Significance of aromatase activity in human breast cancer. Cancer Res 42 (1982) 3365-3368
6. O'Neill J.S., Elton R.A., and Miller W.R. Aromatase activity in adipose tissue from breast quadrants: a link with tumour site. Br Med J (Clin Res Ed) 296 (1988) 741-743
7. O'Neill J.S., and Miller W.R. Aromatase activity in breast adipose tissue from women with benign and malignant breast diseases. Br J Cancer 56 (1987) 601-604
8. Singletary S.E., Allred C., Ashley P., et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 20 (2002) 3628-3636
9. Ozsahin M., Crompton N.E., Gourgou S., et al. CD4 and CD8 T-lymphocyte apoptosis can predict radiation-induced late toxicity: a prospective study in 399 patients. Clin Cancer Res 11 (2005) 7426-7433
10. Ho A.Y., Atencio D.P., Peters S., et al. Genetic predictors of adverse radiotherapy effects: the Gene-PARE project. Int J Radiat Oncol Biol Phys 65 (2006) 646-655
11. ICRU. Report 62: prescribing, recording and reporting photon beam therapy (supplement to ICRU report 50) (1999), International Commission on Radiation Units and Measurements, Bethesda
12. Trotti A., Colevas A.D., Setser A., et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13 (2003) 176-181
13. Aaronson N.K., Ahmedzai S., Bergman B., et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85 (1993) 365-376
14. Sprangers M.A., Groenvold M., Arraras J.I., et al. The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J Clin Oncol 14 (1996) 2756-2768
15. Chargari C., Toillon R.A., MacDermed D., Castadot P., and Magné N. Concurrent hormone and radiation therapy in patients with breast cancer: what is the rationale?. Lancet Oncol 10 (2009) 53-60
16. Azria D., Pelegrin A., Dubois J.B., Mirimanoff R.O., and Ozsahin M. Radiation therapy and tamoxifen: concurrent or sequential? It's no longer the question!. J Clin Oncol 23 (2005) 4239-4241
17. Azria D., Gourgou S., Sozzi W.J., et al. Concomitant use of tamoxifen with radiotherapy enhances subcutaneous breast fibrosis in hypersensitive patients. Br J Cancer 91 (2004) 1251-1260
18. Bentzen S.M., Skoczylas J.Z., Overgaard M., and Overgaard J. Radiotherapy-related lung fibrosis enhanced by tamoxifen. J Natl Cancer Inst 88 (1996) 918-922
19. Koc M., Polat P., and Suma S. Effects of tamoxifen on pulmonary fibrosis after cobalt-60 radiotherapy in breast cancer patients. Radiother Oncol 64 (2002) 171-175
20. Colletta A.A., Wakefield L.M., Howell F.V., et al. Anti-oestrogens induce the secretion of active transforming growth factor beta from human fetal fibroblasts. Br J Cancer 62 (1990) 405-409
21. Canney P.A., and Dean S. Transforming growth factor beta: a promotor of late connective tissue injury following radiotherapy?. Br J Radiol 63 (1990) 620-623
22. Dubray B., Delanian S., and Lefaix J.L. Late effects of mammary radiotherapy on skin and subcutaneous tissues. Cancer Radiother 1 (1997) 744-752
23. Bentzen S.M. Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology. Nat Rev Cancer 6 (2006) 702-713
24. Schnarr K., Boreham D., Sathya J., Julian J., and Dayes I.S. Radiation-induced lymphocyte apoptosis to predict radiation therapy late toxicity in prostate cancer patients. Int J Radiat Oncol Biol Phys 74 (2009) 1424-1430
25. Hallahan D.E., and Virudachalam S. Intercellular adhesion molecule 1 knockout abrogates radiation induced pulmonary inflammation. Proc Natl Acad Sci USA 94 (1997) 6432-6437
26. Crompton N. Programmed cellular response to ionizing radiation. Acta Oncol 37 (1998) 129-142
27. Voll R.E., Herrmann M., Roth E.A., Stach C., and Kalden J.R. Immunosuppressive effects of apoptotic cells. Nature 390 (1997) 350-351
28. Nuynh M.-L., Fadok V.A., and Henson P.M. Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-β1 secretion and the resolution of inflammation. J Clin Invest 109 (2002) 41-50
29. Azria D., Rosenstein B.S., and Ozsahin M. Radiation-induced side effects with or without systemic therapies: prime time for prediction of individual radiosensitivity. Int J Radiat Oncol Biol Phys 71 (2008) 1293-1294
30. Azria D., Ozsahin M., Kramar A., et al. Single nucleotide polymorphisms, apoptosis, and the development of severe late adverse effects after radiotherapy. Clin Cancer Res 14 (2008) 6284-6288